Ron A Mathôt

1. MOLENAAR, Remco J., COELEN, Robert JS, KHURSHED, Mohammed, ROOS, Eva, CAAN, Matthan WA, LINDE, Myra E van, KOUWENHOVEN, Mathilde, BRAMER, Jos AM, BOVÉE, Judith VMG, MATHÔT, Ron A, KLÜMPEN, Heinz-Josef, LAARHOVEN, Hanneke WM van, NOORDEN, Cornelis J. F. van, VANDERTOP, W Peter, GELDERBLOM, Hans, GULIK, Thomas M van, WILMINK, Johanna W. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2- mutated solid tumours. BMJ open. 2017, vol. 7, iss. 6, str. 1-12. ISSN 2044-6055. http://bmjopen.bmj.com/content/7/6/e014961, DOI: 10.1136/bmjopen-2016-014961. [COBISS.SI-ID 4635727]

2. KHURSHED, Mohammed, MOLENAAR, Remco J., LINDE, Myra E van, MATHÔT, Ron A, STRUYS, Eduard A., WEZEL, Tom van, NOORDEN, Cornelis J. F. van, KLÜMPEN, Heinz-Josef, BOVÉE, Judith V. M. G., WILMINK, Johanna W. A phase Ib clinical trial of metformin and chloroquine in patients with IDH1-mutated solid tumors. Cancers. 2021, vol. 13, iss. 10, str. 1-16, ilustr. ISSN 2072-6694. https://www.mdpi.com/2072-6694/13/10/2474, DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije, DOI: 10.3390/cancers13102474. [COBISS.SI-ID 97801987]

3. HANŽEL, Jurij, BUKKEMS, Laura H., GECSE, Krisztina B, D'HAENS, Geert, MATHÔT, Ron A. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Alimentary pharmacology & therapeutics. 2021, vol. 54, iss. 10, str. 1309-1319. ISSN 0269-2813. DOI: 10.1111/apt.16609. [COBISS.SI-ID 78591491]

4. HANŽEL, Jurij, BUKKEMS, Laura H., GECSE, Krisztina B, D'HAENS, Geert, MATHÔT, Ron A. Editorial : subcutaneous CT-P13 in Crohn’s disease and ulcerative colitis–small change, big consequences : authors' reply. Alimentary pharmacology & therapeutics. 2022, vol. 55, iss. 2, str. 253-254. ISSN 0269-2813. DOI: 10.1111/apt.16724. [COBISS.SI-ID 96236803]

5. HANŽEL, Jurij, DRESSEN, Erwin, VERMEIRE, Séverine, LÖWENBERG, Mark, HOENTJEN, Frank, BOSSUYT, Peter, CLASQUIN, Esmé, BAERT, Filip, D'HAENS, Geert, MATHÔT, Ron A. Pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with crohn disease : posthoc analysis of the LOVE-CD study. Inflammatory bowel diseases. [Online ed.]. 2022, vol. 28, iss. 5, str. 689-699. ISSN 1536-4844. https://watermark.silverchair.com/izab044.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAr0wggK5BgkqhkiG9w0BBwagggKqMIICpgIBADCCAp8GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM6_bKi3zNnaQlGrP7AgEQgIICcExHuSHYpcRoXB5lzwHZeoJ-KbskLYT4n8eqAf09CyLhttps://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izab143/6301858, Repozitorij Univerze v Ljubljani – RUL, DOI: 10.1093/ibd/izab143. [COBISS.SI-ID 67785475]